Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Insulet Reports Fourth Quarter Revenue of $130.5 Million, Up 26%, and Gross Margin Up 210 Basis Points, Exceeding Expectations
Full Year 2017 Revenue of $463.8 Million , Up 26%, and Gross Margin Up 230 Basis Points Full Year 2018 Expected Revenue Growth of 21% to 25% BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 21, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless insulin pump
View HTML
Toggle Summary Insulet Has Strong Presence at the International ATTD Congress; Presents Positive Study Results for Its Omnipod Horizon™ Hybrid Closed-Loop System
Significant Presence at ATTD Congress Demonstrates Insulet’s Future Commitment to the Diabetes Community in Europe Studies Show Exceptional Potential for the Omnipod Horizon System to Maintain Stable Blood Glucose Levels after Specific Meal and Exercise Challenges BILLERICA, Mass.
View HTML
Toggle Summary Insulet Corporation to Announce Fourth Quarter and Full Year 2017 Financial Results on February 21, 2018
BILLERICA, Mass. --(BUSINESS WIRE)--Jan. 29, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the fourth quarter and full year
View HTML
Toggle Summary Medicare Part D (Prescription Drug) Plans May Now Cover Omnipod®
Significantly Expands Access to Omnipod and Provides a Pathway to Broader Medicaid Coverage BILLERICA, Mass. --(BUSINESS WIRE)--Jan. 8, 2018-- Insulet Corporation  (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ®  Insulin Management System
View HTML
Toggle Summary Insulet Corporation to Present at Upcoming Investor Conference
BILLERICA, Mass. --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco,
View HTML
Toggle Summary Insulet Corporation to Present at Upcoming Investor Conference
BILLERICA, Mass. --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at the 29th Annual Piper Jaffray Healthcare Conference in New York City ,
View HTML
Toggle Summary Insulet Corporation to Present at Upcoming Investor Conference
BILLERICA, Mass. --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at the Jefferies 2017 London Healthcare Conference on November 15, 2017 , at
View HTML
Toggle Summary Insulet Announces Pricing of Convertible Senior Notes Due 2024
Proceeds for General Corporate Purposes, Including Repurchase of a Portion of Outstanding 2% Convertible Senior Notes Due 2019 and Investment in Manufacturing Operations and International Expansion BILLERICA, Mass. --(BUSINESS WIRE)-- Insulet Corporation  (NASDAQ: PODD) (Insulet or the Company), a
View HTML
Toggle Summary Insulet Announces Private Offering of Convertible Senior Notes
BILLERICA, Mass. --(BUSINESS WIRE)-- Insulet Corporation  (NASDAQ:PODD) (Insulet or the Company), a leader in tubeless insulin pump technology with its Omnipod ®  Insulin Management System (Omnipod System), today announced its intention to offer, subject to market and other conditions, $300 million
View HTML
Toggle Summary Insulet Reports Third Quarter 2017 Financial Results
Third Quarter Revenue of $121.8 Million , Up 28% Year-Over-Year, Exceeds Expectations; Gross Margin Improves to 60.5% Insulet Raises Full Year 2017 Revenue Guidance to a Range of $456 to $459 million , Up from $440 to $450 Million , Representing Growth of 25% at Mid-Point BILLERICA, Mass.
View HTML
Toggle Summary Insulet Corporation Raises Awareness for Diabetes Community During National Diabetes Awareness Month
Highlights Include Fundraising Events and NASDAQ Closing Bell Ceremony BILLERICA, Mass. --(BUSINESS WIRE)-- Insulet Corporation  (NASDAQ: PODD) (Insulet or the Company) the leader in  tubeless insulin pump  technology with its Omnipod ®  Insulin Management System (Omnipod System), is recognizing
View HTML
Toggle Summary Insulet and Dexcom Partner to Offer Choices for Animas Users
Insulet's Welcome Program for Animas ® Users Now Includes Optional Dexcom G5 ® Mobile CGM Upgrade BILLERICA, Mass --(BUSINESS WIRE)-- Insulet Corporation  (NASDAQ: PODD) (Insulet or the Company) the leader in  tubeless insulin pump  technology with its Omnipod ®  Insulin Management System (Omnipod
View HTML
Toggle Summary Insulet Offers Welcome Program for Animas® Users to Try Omnipod® Insulin Management System at Zero Cost
BILLERICA, Mass. --(BUSINESS WIRE)-- Insulet Corporation's  (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ®  Insulin Management System (Omnipod System), is offering the Omnipod ® Welcome Program for existing Animas ® insulin pump users as
View HTML
Toggle Summary Insulet Corporation to Announce Third Quarter 2017 Financial Results on November 2, 2017
BILLERICA, Mass. --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the third quarter of 2017 on November 2, 2017
View HTML
Toggle Summary Insulet Breaks Ground on New U.S. Manufacturing Facility
$100 Million Investment in Massachusetts Will Provide for Hundreds of Local Manufacturing Jobs at a 350,000 Square-Foot Facility BILLERICA, Mass. --(BUSINESS WIRE)-- Insulet Corporation  (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ®
View HTML